Weekly Low-Dose Iron May Reduce Overall Iron Use
Smaller and more frequent IV iron dosing may result in a significant overall reduction in total iron use, according to a study presented at ASN’s Renal Week 2009.
Renal Week 2009 Anemia
Why Large Doses of IV Iron Decrease HD Patient Survival Is Unclear
Very large doses of IV iron are associated with decreased long-term survival in patients on hemodialysis, but a new analysis presented at ASN’s Renal Week 2009 in San Diego probing this association could not establish a convincing reason for the increased mortality.
Anemia Hikes Long-Term Mortality in Non-Diabetic CKD Patients
Anemia in non-diabetic CKD patients increases their risk of long-term mortality, and this predominantly explained by the association between anemia and degree of renal function, according to a study presented at ASN’s Renal Week 2009.
Replacing HD Water Treatment Components Raises Hemoglobin Levels
Preemptive replacement of hemodialysis (HD) water treatment components could result in significantly increased hemoglobin levels at lower doses of erythropoiesis-stimulating agents in HD patients, British researchers reported in a study presented at Renal Week 2009.
Wasting, Inflammation Hike Death Risk in Dialysis Patients with EPO Resistance
Dialysis patients who have erythropoietin resistance also suffer from wasting, inflammation, or both, which increases their risk of death, according to researchers in The Netherlands who presented their study at Renal Week 2009.
Hemoglobin Levels Linked to Vitamin D in Diabetic CKD Patients
Elevated levels of vitamin D are associated with higher hemoglobin levels in CKD patients with diabetes, according to researchers at the University of Missouri School of Medicine in Columbia in a study presented at ASN’s Renal Week 2009.
Data May Help Explain Beneficial Effect of Pentoxifylline in Dialysis Patients with Anemia
Pentoxifylline has been reported to improve resistance to erythropoiesis-stimulating agents. New preliminary findings suggest that part of this beneficial effect may be related to better mobilization and utilization of iron in dialysis patients with anemia, according to a study presented at ASN’s Renal Week 2009.
Ferric Carboxymaltose Safely Improves Hemoglobin in Dialysis Patients
Ferric carboxymaltose given as an IV bolus push injection is well tolerated and effective in correcting hemoglobin levels in hemodialysis patients with iron-deficiency anemia, Romanian researchers reported in a study presented at American Society of Nephrology’s Renal Week.
Higher Hemoglobin May Cut Risk of Death, Dialysis Initiation
Higher hemoglobin levels reduce the risk of death and dialysis initiation among patients with CKD, according to data presented at ASN’s Renal Week 2009.
Heart Failure, Diabetes Attentuate Risk of High Hemoglobin
New data suggest that the presence of comorbidities such as heart failure or diabetes renders increased risk of death and cardiovascular morbidity associated with high hemoglobin targets clinically undetectable, according to analysis presented at ASN’s Renal Week 2009.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Renal Week 2009 Anemia
Loading... 
Loading...